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license (http://creativerelated proteins, and cognitive deficits late in life in both rodents and primates. This study was con-
ducted to investigate if these late life changes were accompanied by epigenetic alterations.
Methods: Western blot analysis and RT-PCR were used to measure Deoxyribonucleic acid methyl-
ation regulators (DNMT1, DNMT3a, MeCP2, MAT2A) and histone proteins (H3K9Ac, H3K4me2,
H3K27me3).
Results: Cerebral levels of DNMT1 and MeCP2 were significantly reduced in mice exposed to Pb
early in life, whereas the expression of DNMT3a was not altered. Levels of MAT2a were increased
in the Pb-exposed mice across the lifespan. H3K9Ac and H3K4me2, involved in gene activation,
were decreased, whereas the repressive mark H3K27me3 was elevated.
Discussion: Epigenetic modifiers are affected by the developmental exposure to Pb and may play a
role in mediating the latent increases in AD-related proteins in the brain.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Aging; Alzheimer’s disease; Epigenetics; Lead (Pb); Lifespan1. Introduction
According to the 2015 Alzheimer’s Report, there are
currently 5.3 million Americans living with AD [1]. The vast
majority of these individuals (.95%) are aged 65 years,
with a disease subtype known as late-onset AD (LOAD). The
remaining 5% of cases make up early-onset AD (EOAD), and
of these (,1%) are linked to mutations in one of three genes,
Amyloid Precursor Protein (APP), Presenilin-1 (PSEN1), and
Presenilin-2 (PSEN2) [2]. LOAD is challenging to researchers,
the presentation of the disease is sporadic as patients exhibitent: The authors declare no potential conflict of
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commons.org/licenses/by-nc-nd/4.0/).non-Mendelian characteristics. To date, there is no clear genetic
etiology for LOAD, other than a risk factor of carrying specific
susceptibility alleles [3,4]. The single and only proven risk
factor for the development of this sporadic form of AD is
aging. These observations suggest the involvement of
environmental and/or epigenetic factors across the lifespan in
the initiation and development of the disease [5].
Early studies have provided evidence that many chronic
adult diseases and disorders, such as cardiovascular disease,
diabetes, and obesity, are linked to environmental exposures
that occurred during development [6,7]. Importantly, there is
also a growing body of literature to support the contention
that exposures to environmental toxins in early life
contribute to the development of at least some of the
neurodegenerative disorders [8].
There are few epidemiologic studies examining the link
between environmental exposures and development ofimer’s Association. This is an open access article under the CC BY-NC-ND
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past exposures to pesticides, metals, dietary changes, and
other environmental influences; however, the results have
been limited. We have taken a specific interest in the envi-
ronmental agent and heavy metal lead (Pb). Pb has been
implicated as a neurotoxin for generations, and is known
to have devastating consequences for the nervous system
specifically in children [9]. The metal is nondegradable,
ubiquitously found in nature, has high bioavailability, can
cross the blood brain barrier and has a long half life [10].
Epidemiologic studies assessing both occupational exposure
and exposures in community-dwelling individuals have
identified Pb as a clear disrupter of cognitive performance
and function [11,12].
Our laboratory was among the first to provide evidence
that exposure to an environmental Pb in early life results
in latent overexpression of AD-related proteins and histopa-
thology in late life [13–16]. Reports by us have also
demonstrated a latent increase in both amyloidogenic and
tauogenic proteins, as well as behavioral deficits in our
rodent models [13,17]. These results have been replicated
and further investigated in a primate model, where we
have also reported the presence of tangles and plaques in
the cerebral cortex [14,16]. More recently, we have shown
that the changes in the expression of proteins such as APP,
amyloid beta (Ab), and microtubule-associated protein tau
are accompanied by epigenetic changes [14,18].
Epigenetics refers to the process that results in
modifications in gene activity independent of the primary
deoxyribonucleic acid (DNA) sequence [19]. DNA methyl-
ation alterations and histone tail modifications are the most
widely studied forms of epigenetic modifications.
This study documents the expression of four enzymes
important in regulating DNA methylation and three histone
modifications (two activating, one repressive) across the life-
span of animals that were exposed to Pb during a brief period
of early postnatal life. Our results provide a valuable frame-
work for understanding a number of epigenetic interactions
that likely play a critical role in the expression of neurotoxic
AD-related proteins in later life. This work is the first to
identify epigenetic changes across the lifespan after a devel-
opmental exposure that has been previously shown to have
significant increases in AD-related biomarkers.2. Methods
2.1. Animal exposure
C57BL/6 mice were bred in house in the Animal Care
Facility at the University of Rhode Island, according to pre-
viously published protocols [15,17]. All experiments were
performed in accordance with the standard guidelines and
protocol approved by the University of Rhode Island
Institutional Animal Care and Use Committee (IACUC)
with supervision of the university’s veterinarian. Males
were divided into two groups and used in this study. Thecontrol group received regular tap water, whereas the
second group (PbE, developmental exposure) was exposed
to 0.2% Pb-acetate from PND 1 to PND 20 through the
drinking water of the dam. Animals receiving Pb acetate
had no observable adverse developmental deficits. Brains
were dissected at the following ages: PND 20, 180, 270,
540, and 700 and stored at 280C until use. These animals
are from the subset of the same cohort that has already
been characterized for Alzheimer’s pathology and behav-
ioral deficits [15,17].2.2. Total RNA isolation, synthesis of cDNA, and real-time
PCR
Total RNAwas isolated from the cerebral cortex after the
TRIzol method (Invitrogen, Carlsbad, CA). Samples were
checked for integrity and purity by NanoDrop (Thermo
Fischer Scientific, Waltham, MA). First-strand complemen-
tary DNA (cDNA) was synthesized using the iScript cDNA
Synthesis Kit (Bio-Rad, Hercules, CA). Approximately 1 mg
of RNAwas diluted in 19 mL of water, with 4 mL 5! iScript
reaction mix, and 1 ml of iScript reverse transcriptase. Sam-
ples were incubated at 42C for 90 minutes, followed by
85C for 5 minutes using the MJ Research MiniCycler
PTC-150 (Bio-Rad). Real-time PCR was carried out in
12.5-mL reaction volumes containing 1 ml of cDNA tem-
plate, 4.75-ml nuclease free water, and 6.25-ml SYBR Green
PCR Master Mix (Applied Biosystems, Foster City, CA).
Real-time PCR was performed using the ViiA7 Real-Time
PCR System (Applied Biosystems) using the following con-
ditions: 50C for 2 minutes followed by 95C for 10 minutes
then 40 cycles of 95C for 15 seconds and 60C for 1 minute.
Expression data were reported using the 22DDCT method and
GAPDHmRNA as the endogenous control. The primer pairs
used are summarized in Table 1.2.3. Protein extraction
For DNMT1, DNMT3a, andMECP2, the nuclear fraction
was collected according to the method described by Dignam
et al, with minor modifications [20]. Samples were homog-
enized in 1-ml phosphate buffer saline at pH 7.4 followed by
centrifugation at 2500 ! g for 10 minutes. The pellets ob-
tained were resuspended in 5 volumes of buffer A (10-mM
HEPES, pH 7.9, 1.5-mM MgCl2, 0.5-mM DTT, 0.5-mM
EDTA, and 0.2-mM PMSF) and centrifuged at 600 ! g
for 2 minutes at 4C. The pellets were resuspended in 3 vol-
umes of buffer A and centrifuged at 600! g for 2 minutes at
4C. After centrifugation, pellets were then resuspended and
homogenized in 5 vol of buffer C (20-mM HEPES, pH 7.9,
1.5-mM MgCl2, 0.5-mM DTT, 0.5-mM EDTA, 420-mM
NaCl, 20% glycerol, 0.2-mM PMSF, 2-mg/ml aprotinin,
and 0.5-mg/ml leupeptin). Suspensions were centrifuged at
12,000 ! g for 10 minutes at 4C. supernatants were
collected, frozen, and stored at 280C until use. Cyto-
plasmic protein samples were isolated using the NE-PER
Table 1
Primer sequence pairs used in the study for the analysis of gene expression
Gene Forward primer Reverse primer
DNMT1 50-GAGTCTTCGACGTCACACCA-30 50-AGCTACCTGCTCTGGCTCTG-30
DNMT3a 50-CTTGGAGAAGCGGAGTGAAC-30 50-GGATTCGATGTTGGTCTGT-30
MeCP2 50-CAGCAGCATCTGCAAAGAAG-30 50-TCCACAGGCTCCTCTCTGTT-30
MAT2A 50-ACCCTATGCATGGTTTCAGC-30 50-ACCCTGGGAGGAGCTATTG-30
GAPDH 50-AGGTCGGTGTGAACGATTTG-30 50-TGTAGACCATGTAGTTGAGGTCA-30
B-ACTIN 50-TGTTACCAACTGGGACGACA-30 50-TCTCAGCTGTGGTGGTGAAG-30
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manufacturer’s instructions (Thermo Fischer Scientific).2.4. Histone extraction
Total histones were extracted using the EpiQuick Total
Histone Extraction Kit (Epigentek, Farmingdale, NY)
following the manufactures instructions, with minor modifi-
cations. Cortical tissue was weighed and cut into 1–2 mm
pieces and homogenized at 200 mg/mL with prelysis buffer.
The homogenate was centrifuged at 10,000 rpm for 1 minute
at 4C. The supernatant was discarded, and the pellet was re-
suspended in 3 ! volume of lysis buffer and incubated on
ice for 30 minutes. The sample was centrifuged at
12,000 ! g for 5 minutes at 4C, and the supernatant was
transferred to a fresh vial. Balance buffer was added to the
supernatant (0.3 mL to 1 mL supernatant). The extract was
placed at 280C for long-term storage.2.5. Western blot analysis
Protein concentration was determined by using the Mi-
cro BCA Protein Assay Kit (Thermo Fischer Scientific).
Protein samples were then denatured and separated by so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) at 150 V for 1–2 hours and then transferred
to polyvinyl diflouride (PVDF) membranes (GE Health-
care, Piscataway, NJ), blocked for 1 hour with 5% bovine
serum albumin and then immunoblotted with the appro-
priate primary antibody. For MAT2A, 40 mg of cytoplasmic
extracts were separated on 10% SDS-PAGE gels and incu-
bated overnight with primary polyclonal antibody at the
dilution 1:1000 of ab77471 (Abcam, Cambridge, UK).
Membranes were then stripped and reprobed with 1:2000
dilution of monoclonal A3854 (Sigma-Aldrich, St. Louis,
MO) for b-actin. For DNMTs and MeCP2 proteins,
100 mg of nuclear extracts were separated on 5% SDS-
PAGE gels and incubated overnight with primary mono-
clonal antibodies (Cell Signaling, Danvers, MA) 1:1000
dilution of D59A4 for DNMT1, D23G1 for DNMT3a,
and D4F3 for MeCP2. Membranes were then stripped
and reprobed with 1:2000 dilution of G8795 (Sigma-Al-
drich, St. Louis, MO) for Glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH). For histone proteins, the following
primary polyclonal antibodies (Epigentek) were used at a
1:5000 dilution, A-4022 for H3K4me2, A-4022 forH3K9Ac, A-4039 for H3K27me3, A-4035 for H3K9me3,
and A-1112 for total H3. Ten micrograms of histones
were separated onto 16% gels and incubated overnight
with the respective primary antibody. Membranes were
then washed four times with tris buffered saline with
Tween 20 (TBST) and incubated with appropriate
infrared-labeled secondary antibody (Li-Cor, Lincoln,
NE) at 1:10,000 for 1 hour at room temperature in the
dark. Infrared band signals were detected and quantified
using an Odyssey Infrared Imaging System (Li-Cor).
MAT2A protein was normalized against b-actin, whereas
nuclear proteins were normalized against levels of the
housekeeping protein GAPDH. Histone proteins were
normalized against bands for total H3.2.6. Statistical analysis and data representation
Western blot analysis was performed using the Odyssey
Infrared Imaging System (Li-Cor, Lincoln, NE). Real-time
PCR analysis was completed using the applied biosystems
ViiA7 software. Each data set has either an n 5 3 or n 5 4
(designated in the figure legend), the animals were measured
independently without pooling of brain tissue or samples. In-
dividual data points are presented on each graph, as well as
the mean for each group. The vertical bars represent 95%
confidence intervals and are shown for each data set. The
significance of difference between different treatment
groups was determined by one-way analysis of variance
(ANOVA), with the Holmes–Sidak post hoc test using
IBMSPSS statistics 21 software. The significance of interac-
tion between treatment groups and time was determined by
two-way analysis of variance. The level of significance was
set at a5 0.05. The change in protein levels with respect to
each time point was analyzed by ANOVAwith the Dunnetts
post hoc test.3. Results
We have previously measured Pb concentrations in ani-
mals exposed under the same protocol as the one in this
manuscript and found the concentration of Pb in the cere-
bellum of PND 20 rodents (0.25 1/2 0.07 mg/g) to be
approximately three times the level seen in control animals
[21]. Blood levels have been shown to be 46.43 mg/dl during
Pb exposure but are reduced to basal levels in adults [13].
The current recommended levels by the CDC is that of
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scenario are higher, they are still consistent with the levels
seen in both children and adults exposed to environmental
Pb [22,23].3.1. Effect of Pb exposure on the expression of DNMT1
and 3a protein
There was no significant interaction effect between Pb
treatment and time. The exposed mice had a statistically sig-
nificant decrease in normalized DNMT1 levels at all time-
points across lifespan relative to the control animals. In
both the control group and Pb-exposed animals, DNMT1 pro-
tein expression was decreased at all timepoints relative to
PND 20 (Fig. 1A). Unlike DNMT1 protein levels, DNMT3a
showed no significant difference between control and Pb-
exposed animals across the lifespan of the mice (Fig. 1B).3.2. Levels of MeCP2 protein across the lifespan after
exposure
MeCP2 protein levels normalized relative to GAPDH are
increased at day 270 in both the control and Pb-exposed an-
imals; however, these results are not significant. Statistically
significant decreases between the Pb-exposed group and the
control group are observed at day 180 and 540 as seen in
Fig. 2A. The remaining timepoints exhibited no significant
difference between Pb exposed and controls. The control
group exhibited no differences in proteins levels from
PND 20 at any other time point. Whereas in the Pb-Fig. 1. DNA methyltransferase (DNMT) protein levels across the lifespan after d
levels across the lifespan for control animals and those developmentally exposed t
developmental Pb exposure. (C) Representative DNMT1 and DNMT3a proteins lev
analysis as described in the methods section. Individual data points are represented
is represented as **P, .01, ***P, .001. ySignificance from the PND20 group for
time point for the lead exposure group.exposed animals, there was significant differences in protein
expression observed at all timepoints except for PND 270.
There was also no significant interaction effect between Pb
treatment and time.3.3. Protein levels of MAT2A protein across the lifespan
and after Pb exposure
The cytoplasmic protein expression profile of MAT2A
across the lifespan of control groups did not display any signif-
icant change (Fig. 2). However, mice exposed to Pb as infants
demonstrated a statistically significant increase in levels of
MAT2A at day 270, 540, and 700 relative to control. Similarly,
there is no interaction effect between time and treatment.3.4. Alterations in gene expression of DNAmediators after
Pb exposure
Changes in gene expression of Dnmt1, Dnmt3a, and
Mecp2 were also examined by real-time PCR analysis.
We observed no significant difference between mRNA
levels of Dnmt1, across the lifespan between the control
and Pb exposed animals (Fig. 3A). Dnmt3a mRNA levels
for the Pb-exposed animals were elevated compared to
controls across the lifespan and significantly increased
at PND 20 (Fig. 3B). In Fig. 4C, mRNA for MeCP2 is
significantly lower at PND 20 and PND 270 for the
exposed group, with no change at any other time point.
There was no significant interaction effect for any of these
mRNA targets.evelopmental exposure to lead (Pb). (A) Quantification of DNMT1 protein
o Pb. (B) Quantification of DNMT3a protein levels across the lifespan after
els. Nuclear extracts were used, and proteins were measured by western blot
on the graph, as well as the means for each time point. N5 3 and significance
the control animals, while # is used to denote significance from the PND20
Fig. 2. Methyl CpG binding protein 2 (MeCP2) andMethionine adenosyltransferase 2a (MAT2a) levels across the lifespan after developmental exposure to lead
(Pb). (A) Quantification ofMeCP2 protein expression levels across the lifespan for control animals and those developmentally exposed to Pb. (B) Quantification
of MAT2A protein expression levels across the lifespan for control animals and those developmentally exposed to Pb. (C and D) Representative MeCP2 and
MAT2A protein levels. Nuclear and cytoplasmic extracts were used, and proteins were measured by western blot analysis as described in the methods section.
Individual data points are represented on the graph, as well as the means for each time point. N 5 3 for MeCP2 and N 5 4 for MAT2A, and significance is
represented as **P , .01, ***P , .001. #Significance from the PND20 time point for the lead exposure group.
Fig. 3. mRNA levels of DNA methylation regulators across the lifespan after developmental exposure to lead (Pb). (A) Quantification of Dnmt1 mRNA
across the lifespan for control animals and those developmentally exposed to Pb. (B) Quantification ofDnmt3amRNA across the lifespan for control animals
and those after infantile exposure. (C) Quantification of Mecp2 mRNA across the lifespan for control animals and those developmentally exposed to Pb.
Individual data points are represented on the graph, as well as the means for each time point. N 5 3 or N 5 4 and significance is represented as
**P, .01, ***P, .001. y Significance from the PND20 group for the control animals. # Significance from the PND20 time point for the lead exposure group.
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Fig. 4. Activating histone protein levels across the lifespan after developmental exposure to lead (Pb). (A) Quantification of H3K9Ac protein expression levels
across the lifespan for control animals and those developmentally exposed to Pb. (B) Quantification of H3K4me2 protein levels across the lifespan after devel-
opmental Pb exposure. (C) Representative histone proteins levels. Histone extracts were used, and proteins were measured by western blot analysis as described
in the methods section. Individual data points are represented on the graph as well as the means for each time point. Individual data points are represented on the
graph, as well as the means for each time point.N5 3 and significance is represented as *P, .05, **P, .01, ***P, .001. ySignificance from the PND20 group
for the control animals. #Significance from the PND20 time point for the lead exposure group.
Fig. 5. Repressive histone mark levels across the lifespan after develop-
mental exposure to lead (Pb). (A) Quantification of H3K27me3 protein
expression levels across the lifespan for control animals and those develop-
mentally exposed to Pb. (B) Representative H3K27me3 protein levels. His-
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marks across the lifespan
Histone extracts were used to profile histone modification
marks across the lifespan via western blot. The activating
marks are shown in Fig. 4. H3K9Ac protein levels were
significantly lower in the Pb-exposed mice for all timepoints
except PND 20, as seen in Fig. 4A. In the control animals,
there were significant differences compared to PND 20 at
both PND 270 and 540, and in the Pb-exposed animals, signif-
icance was observed at all timepoints relative to day 20.
H3K4me2 levels have a similar trend, the Pb exposed mice
have lower protein levels compared to controls across the life-
span, with the only significant decrease occurring at PND 20
(Fig. 5B). Similarly, there were no significant changes at any
of the timepoints relative to day 20 in either the control group
or Pb-exposed group. Representative blots for H3K9Ac and
H3K4me2 are seen in Fig. 4C, with total Histone H3 as a
loading control. Protein levels for H3K27me3 are shown in
Fig. 5. H3K27me3 is a histonemark indicative of gene repres-
sion. Pb-exposed animals showed significantly higher levels
of H3K27me3 across the lifespan except for day 180. In the
control animals, all timepoints exhibited significant differ-
ences relative to PND 20, whereas in the Pb-exposed animals
significance was only observed at PND 270 and PND 540. A
representative blot for H3K27me3 is shown in Fig. 5B.tone extracts were used, and proteins were measured by western blot
analysis as described in the methods section. Individual data points are rep-
resented on the graph, as well as the means for each time point. N 5 3 and
significance is represented as *P , .05, **P , .01. y Significance from the
PND20 group for the control animals. # Significance from the PND20 time
point for the lead exposure group.4. Discussion
Epigenetic regulation is a complicated phenomenon with
converging pathways involved in the regulation of geneexpression. DNA methylation is maintained by DNA meth-
yltransferases such as DNMT1, DNMT3a, and DNMT3b
and involves the recruitment of MeCP2 and other proteins
[24]. Typically, recruitment of methyl groups and methyl
binding proteins is indicative of a decrease in gene expres-
sion and is associated with repressive complexes [25].
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matin that are open to transcription and typically indicate
gene activation. Histone methylation marks such as
H3K27me3 and H3K9me3 are associated with regions of
condensed chromatin and gene repression.
This in-vivo study uncovered a significant decrease in
DNMT1 levels relative to their age-matched controls
across the lifespan of mice developmentally exposed to
Pb, with a significant decrease in MeCP2 levels at some
timepoints as well. These findings are consistent with
our previously published results indicating that differenti-
ated SHSY5Y cells treated with increasing concentrations
of Pb have a significant decrease in DNA modification en-
zymes and MeCP2 [18]. DNMT1 is an important regulator
of tissue-specific DNA methylation patterns; exposure to
metals such as Cd has been shown to alter the activity
and protein levels of this enzyme [26]. We have also pre-
viously examined the ability of Pb to alter the activity of
DNMT1 in tissue and have found that exposure to Pb does
decrease DNMT1 activity [14]. Studies from other groups
have also examined changes in protein levels of DNMT1
and MECP2 as a result of postnatal and perinatal Pb expo-
sure [27]. They reported a downregulation in these DNA
methylation modifiers in the hippocampus at PND 55 after
Pb exposure. Our results are consistent with their findings,
indicating that Pb exposure down-regulates these proteins
in the cerebral cortex, and that this repression is never
recovered. The data points collected in our study indicate
that even at PND 700 there is downregulation of DNMT1
and MeCP2 is maintained.
The results obtained from studying the gene expression
of these DNA methylation regulators leads us to believe
that Pb is most likely decreasing their protein expression
directly and perhaps not through transcriptional regulation.
There was no significant change in mRNA levels for
DNMT1, but there was a decrease in protein relative to
controls across the lifespan. A possible mechanism for
this may be due to increases in protein degradation of
DNMT1 after exposure. Similarly, MeCP2 mRNA was
only significantly lower at the PND 20 and PND 270
time point. The most interesting observation obtained
from the gene expression data is for DNMT3a. DNMT3a
gene expression for the Pb treatment was higher across
the lifespan and significantly increased at PND 20, whereas
the protein levels were not significantly different in the lead
exposed animals relative to control. These data are ex-
plained by a recent finding from our laboratory an demon-
strating increase in miR-29b (targeting DNMT3a)
following exposure at PND 20, suggesting that miR-29b
may be inhibiting the translation of the DNMT3a mRNA
[28]. The same article reported an increase of miR-106
(targeting APP) at PND 700 [28]. There is also evidence
that miRNA expression is effected by chronic Pb exposure
in an adult rat hippocampus [29]. Our observations with
DNMT3a are also consistent with previously published
work by our laboratory indicating that DNMT3a geneexpression is 2-fold decreased at PND 700 for the Pb-
treated group as compared to PND 20 in primates [30].
MAT2A catalyzes the formation of S-adenosylmethione
(SAM) frommethione and ATP and is an important regulator
of the methylation cycle. It has been well documented that
SAM levels have been found to be significantly decreased
in the cerebrospinal fluid of patients with AD [31]. In our
study, we have shown that Pb-exposed mice have elevated
levels of MAT2A across the lifespan compared to their
age-matched controls. A recent study in hepatoma cells
has shown that on hypoxia exposure, DNA demethylation
pathways are activated, whereas MAT2A expression is upre-
gulated [32]. To better understand the role of MAT2A and
the changes of gene expression, we will have to further
investigate its role in regulating the DNA methylation
pathway in our model.
Histone modifications refer to additions of chemical
groups to N-terminus tail of histone proteins, most
commonly the histone core proteins, H3 and H4. Histone
acetylation levels are governed by histone acetyltransferases
(HATs) and deacetylases (HDACs) whereas histone methyl-
ation by histone methyltransferases (HMTs). It is known that
histone modifications and DNA methylation interact to alter
the conformation and thus the accessibility of the promoter
and coding regions of the genome [33]. In this study, we
have shown that early life Pb exposurewas found to decrease
H3K9Ac and H3K4me2 proteins levels, both of which are
marks for gene activation. We have also shown that
H3K27me3 levels are increased, which also is indicative
of gene repression. These are consistent with our previous
findings in our primate tissue, where we observed that his-
tone repressive marks were upregulated, and most genes
are downregulated after Pb exposure [34].
Although much information can be gained from under-
standing the changes in the regulation of DNA methylation
enzymes and proteins, we are limited in that we have not
identified specific genes that are directly affected in the alter-
ation of binding of these modifiers. We are also trying to
investigate the mechanisms by which Pb exposure may
contribute to the dysregulation of these proteins. It appears
from these studies and previous studies, that after Pb expo-
sure, there are groups of genes that are upregulated, and
others that are repressed. This upregulation of specific genes
may be facilitated by DNA hypomethylation, whereas the
gene repression may be histone mediated. The changes
that have been previously reported in this animal model
report increases in AD-related proteins late in life, whereas
the dysregulation observed in the epigenetic regulators oc-
curs throughout the lifespan [15,17]. Future studies will
examine the alterations in DNA methylation, as well as
histone modifications that occur at specific genes and the
consequences that have the expression of those genes. The
implications of this work and the findings obtained from
studying histone modifications and DNA methylation are
vast. Targeting epigenetic marks is becoming recognized
as a novel therapeutic approach for neurodegenerative
A. Eid et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2 (2016) 123-131130disease, including AD [35]. Treatments that have been
explored include histone deacetylase (HDAC) inhibitors,
such as valproic acid and S-adenosylmethionine supplemen-
tation as a method to target DNA methylation changes [35].
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1. Systemic review: We have performed a thorough
literature review to understand the scope of envi-
ronmental risk factors associated with Alzhemier’s
disease (AD), and the potential mechanisms that
mediate their action at various stages of life. We
have identified and cited properly past findings on
the environmental exposures that impact AD-
related genes and the epigenetic mediators associ-
ated with them.
2. Interpretation: Our findings connect past findings re-
ported to occur to AD-related genes to the epigenetic
mechanisms that regulate them. Our results show a
link between early life exposure to Pb and its ability
to reprogram the expression of epigenetic in-
termediates involved in DNA methylation or histone
modification that in turn regulate latent AD-related
gene expression.
3. Future directions: Our findings have helped us under-
stand that DNA methylation and histone modifica-
tions may partially explain the reprogramming of
gene expression in old age due to developmental
exposure. In the future, we plan to study the role of
microRNAs in this process.
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